Brought to you by 
Axcan gets North American rights to Cellerix's Cx401
08 Mar 2011
Executive Summary
Cellerix SL (stem cell therapies) licensed Axcan Pharma (focused on gastrointestinal disorders) exclusive North American rights to Cx401 for perianal fistulas.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com